5 Key Takeaways

• 1

  A new analysis critiques a JAMA study on drug prices cited by Senator Bernie Sanders for its methodological flaws.

• 2

  The JAMA study estimated diabetes medications could be produced for $5 a month, which the PRI brief disputes.

• 3

  The PRI brief highlights the JAMA study's failure to define 'excessive profits,' undermining drug development cost recoupment.

• 4

  The critique emphasizes systemic drug pricing issues, including the role of pharmacy benefit managers and inflated list prices.

• 5

  The pharmaceutical industry invested $101 billion in research and development in 2022, contrasting with JAMA's cost estimates.